MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock and...
$75,000K
Proceeds from
redemptions of short-term...
$36,350K
Proceeds from issuance of
common stock upon...
$1,779K
Proceeds from exercise of
warrants and options
$34K
Proceeds from issuance of
common stock under espp
$18K
Net cash provided by
financing activities
$69,361K
Net cash provided by
(used in) investing...
$36,234K
Canceled cashflow
$7,470K
Canceled cashflow
$116K
Net increase
(decrease) in cash and cash...
$54,713K
Canceled cashflow
$50,882K
Payment of issuance
costs associated with...
$7,441K
Taxes paid related to
net share...
$29K
Accrued liabilities
$8,402K
Stock-based compensation
expense
$6,258K
Accounts payable
$5,543K
Income taxes payable
$1,037K
Depreciation expense
$64K
Purchase of property and
equipment
$116K
Net cash used in
operating activities
-$50,882K
Canceled cashflow
$21,304K
Net loss
-$69,375K
Prepaid expenses and
other assets
$2,574K
Accretion of debt discount
on...
$237K
Back
Back
Cash Flow
source: myfinsight.com
Forte Biosciences, Inc. (FBRX)
Forte Biosciences, Inc. (FBRX)